Recently, a study published in the international journal Nature under the title "Broadly inhibitory antibodies to severe malaria virulence proteins" shows that scientists from institutions such as the University of Texas Health Science Center have discovered a special human antibody that can recognize and target several proteins that cause severe malaria. This breakthrough is expected to help develop new vaccines or anti-malarial therapies in the future. The researchers believe that these antibodies can block the binding of parasites through a similar mechanism, by recognizing three highly conserved amino acids on the CIDRα1 protein. These broadly reactive antibodies may represent a common mechanism of the bodys acquired immunity to severe malaria infection, which provides new insights for the design of PfEMP1-based vaccines or therapies targeting severe malaria. This study may open a door for scientists to develop new methods to protect people from severe malaria, such as vaccines or other therapies.